Ariel International marks the firm’s first foray into foreign-stock investing. It has been a performance success so far.
GENENTECH’S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY
Genentech Presents Positive Results from Pivotal Study of Investigational Immunotherapy Atezolizumab in Specific Type of Advanced Bladder Cancer at 2015 European Cancer Congress
Two Positive Studies of Genentech’s Investigational Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer Presented at 2015 European Cancer Congress
Maxygen MAXY announced that its partner Roche RHHBY placed a hold on development of Maxy-Alpha--the first of Maxygen's shuffled proteins to enter clinical development--and we're lowering our fair value estimate accordingly. While we had only placed a 20% probability on the eventual approval of ...
Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.
First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.
Readers say diversification and exposure to good companies call for looking beyond the U.S.
Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.
These top managers continue to focus on higher-quality dividend-paying stocks in a market that has become more volatile of late.